No Image Available

RF ablation systems

Barrx™ radiofrequency ablation system

<p>The Barrx™ radiofrequency ablation system is used to treat Barrett’s esophagus (BE) patients by eradicating Barrett’s epithelium.</p>

Ordering information
Contact a representative

Features

Explore the Barrx™ radiofrequency ablation system components

Barrx™ flex RFA energy generator

Barrx™ flex RFA energy generator

The Barrx™ flex RFA energy generator is a bipolar radiofrequency generator that provides the flexibility to choose either the Barrx™ 360 express RFA balloon catheter for larger treatment areas or Barrx™ RFA focal catheters for smaller focal areas.

Barrx™ 360 express RFA balloon catheter

Barrx™ 360 express RFA balloon catheter

The Barrx™ 360 express RFA balloon catheter features a self-adjusting ablation balloon that eliminates the sizing process.

PillCam™ SB 3 sensor belt

Barrx™ RFA focal catheters

The Barrx™ RFA focal catheter enables physicians to provide primary treatment for short and intermediate length segments of non-circumferential Barrett's esophagus or provide secondary treatment after ablation with the Barrx™ 360 RFA balloon catheter (or other therapeutic devices).

Barrx™ channel RFA endoscopic catheter

Barrx™ channel RFA endoscopic catheter

The Barrx™ channel RFA endoscopic catheter delivers radiofrequency ablation after being placed through the working channel of a flexible endoscope.

Barrx™ RFA accessories

Barrx™ RFA accessories

Barrx™ accessories include endoscopic guidewires, cleaning caps, and a cart to hold ablation equipment.

When treating Barrett’s esophagus — think beyond surveillance.

Progression of Barrett’s esophagus to esophageal adenocarcinoma (EAC) can be deadly.2 Surveillance may not be enough for some patients. 

Clinical data has identified several risk factors that contribute to disease progression, including: 

  • Dysplasia3,4
  • Family history of Barrett’s esophagus or EAC5
  • Long-segment disease6
  • Smoking tobacco7

Proactively treat Barrett’s esophagus with the Barrx™ radiofrequency ablation system. 

Eradicate Barrett’s esophagus for patients with low-grade dysplasia and reduce the relative risk of disease progression to high-grade dysplasia and esophageal adenocarcinoma by up to 94% with the Barrx™ radiofrequency ablation system.†,3,4,8

Major GI societies endorse radiofrequency ablation in the treatment guidelines for Barrett’s esophagus. With demonstrated efficacy, safety,1 and support from leading institution9,10 this technology allows you to act with confidence.

When risk of progression is high, proactively treat with the Barrx™ radiofrequency ablation system.

Ordering information

Item number Description Units per box
1190A-115A Barrx™ flex RFA energy generator, 115V. Contains 1 Barrx™ flex RFA footswitch and 1 Barrx™ flex RFA output cable included with each generator. 1
FLEXFS-010A Barrx™ flex RFA footswitch, 10' (3 m) 1
FLEXCC-020A Barrx™ flex RFA output cable, 9' (2.7 m) 1
64082 Barrx™ RFA self-sizing balloon catheter 1
90-9300 Barrx™ 60 RFA focal catheter 1
90-9100 Barrx™ 90 RFA focal catheter 1
90-9200 Barrx™ ultra-long RFA focal catheter 1
TTS-1100 Barrx™ channel RFA endoscopic catheter 1
GW-005M 0.038” (0.097 cm) x 230 cm with depth markings 230 cm 1
CP-001A Small: 8.8 mm to 9.7 mm
 10
CP-002A Medium: 9.8 mm to 11.1 mm
 10
CART-100 Barrx™ RFA cart 1

Related links

Capsule Endoscopy System Tech Support Promo Box

Technical support

Get technical support for all endoscopy products.

Email us
Phone: 1-800-448-3644, option 3

† 94% is the calculated relative risk reduction [(26-1.5)/26] = 25/26 100. From [25.0% (1.5% for ablation versus 26.5% for control; 95%CI, 14.1%–35.9%; P < .001].

  1. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42(10):781–789
  2. American Cancer Society. Key statistics for esophageal cancer. Last revised January 2023. Accessed April 2023.

  1. Phoa KN, van Vilsteren FG, Pouw RE, et al. Radiofrequency ablation versus endoscopic surveillance for patients with Barett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12):1209–1217.
  2. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009;360(22):2277–2288.
  3. Tofani CJ, Gandhi K, Spataro J, et al. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus. United European Gastroenterol J. 2019;7(2):225–229.  
  4. Anaparthy R, Gaddam S, Kanakadandi V, et al. Association between length of Barrett’s esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol. 2013;11(11):1430–1436.
  5. Coleman HG, Bhat S, Johnston BT, McManus D, Gavin AT, Murray LJ. Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett’s esophagus. Gastroenterology. 2012;142(2):233–240.
  6. Wolf WA, Pasricha S, Cotton C, et al. Incidence of esophageal adenocarcinoma and causes of mortality after radiofrequency ablation of Barrett’s esophagus. Gastroenterology. 2015;149(7):1752–1761.
  7. Sharma P, Shaheen N, Katzka D, Bergman JGHM. AGA clinical practice update on endoscopic treatment of Barrett's esophagus with dysplasia and/or early cancer: expert review. Gastroenterology. 2020;158(3):760–769.
  8. Shaheen NJ, Falk GW, Iyer PG, Gerson, LB. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2016;111(1):30–50.

These products are licenced with Health Canada as :
BARRX FLEX RFA ENERGY GENERATOR MDL  #73638.
BARRX 360 EXPRESS RFA BALLOON CATHETER MDL #74821.
BARRX RFA FOCAL CATHETER MDL #73342.
BARRX CHANNEL RFA ENDOSCOPIC CATHETERS MDL #91882.
BARRX RFA ENDOSCOPIC GUIDEWIRE COATED, MARKED MDL #104685.
BARRX RFA CLEANING CAP MDL #94648.